Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Joan T Garrett"'
Autor:
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0285251 (2023)
HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3
Externí odkaz:
https://doaj.org/article/005fb3312dc84d4f917dde93496d688e
Autor:
Hima Patel, Rosalin Mishra, Adam Wier, Nazanin Mokhtarpour, Edward J. Merino, Joan T. Garrett
Publikováno v:
Anti-Cancer Drugs. 34:519-531
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d40df613246ee048ae918a5d73a4f436
https://doi.org/10.1097/cad.0000000000001500
https://doi.org/10.1097/cad.0000000000001500
Publikováno v:
Cancer Research. 82:P5-10
HER2 is amplified in about 20% of breast cancers. HER3 is as essential as HER2 for maintaining cell viability in HER2+ breast cancer cells. Inhibition of HER2 tyrosine kinase activity results in upregulation of HER3 transcription and phosphorylation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e45c41f06a3d02c9d93ea0f10183f38
https://doi.org/10.1158/1538-7445.sabcs21-p5-10-05
https://doi.org/10.1158/1538-7445.sabcs21-p5-10-05
Autor:
Carlos L. Arteaga, Christos Sotiriou, Martine Piccart, José Baselga, David Brown, David Venet, Sylvain Brohée, Samira Majjaj, Jan C. Brase, Jens Huober, Heikki Joensuu, Stephen Castellino, M. Reid Groseclose, Jennifer Becker, Philip Owens, Eric Sanford, Garrett M. Frampton, Phillip S. Kim, Sharat Singh, Emma Langley, James P. Koch, Paula González Ericsson, Preston D. Moore, Mónica Valeria Estrada, Joan T. Garrett, Ariella B. Hanker
Table S1. Deep sequencing of ERBB2 does not identify recurrent ERBB2 mutations in LTR tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4a52cd6b60a7b877f482c38af9b70cd
https://doi.org/10.1158/1078-0432.22468419
https://doi.org/10.1158/1078-0432.22468419
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19542c7fa84d3f97736095789a7a7141
https://doi.org/10.1158/1078-0432.c.6522339
https://doi.org/10.1158/1078-0432.c.6522339
Autor:
Carlos L. Arteaga, Christos Sotiriou, Martine Piccart, José Baselga, David Brown, David Venet, Sylvain Brohée, Samira Majjaj, Jan C. Brase, Jens Huober, Heikki Joensuu, Stephen Castellino, M. Reid Groseclose, Jennifer Becker, Philip Owens, Eric Sanford, Garrett M. Frampton, Phillip S. Kim, Sharat Singh, Emma Langley, James P. Koch, Paula González Ericsson, Preston D. Moore, Mónica Valeria Estrada, Joan T. Garrett, Ariella B. Hanker
Supplementary Methods and Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7994a6c8a70f40f1144856986ab07fa8
https://doi.org/10.1158/1078-0432.22468422.v1
https://doi.org/10.1158/1078-0432.22468422.v1
PDF file - 110K, Dose responsiveness of U3-1287 to downregulation of HER3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bfd02973f2fe8f21cc0320a1f3e5129
https://doi.org/10.1158/1078-0432.22451955
https://doi.org/10.1158/1078-0432.22451955
Autor:
Carlos L. Arteaga, Christos Sotiriou, Martine Piccart, José Baselga, David Brown, David Venet, Sylvain Brohée, Samira Majjaj, Jan C. Brase, Jens Huober, Heikki Joensuu, Stephen Castellino, M. Reid Groseclose, Jennifer Becker, Philip Owens, Eric Sanford, Garrett M. Frampton, Phillip S. Kim, Sharat Singh, Emma Langley, James P. Koch, Paula González Ericsson, Preston D. Moore, Mónica Valeria Estrada, Joan T. Garrett, Ariella B. Hanker
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49174e1dbcff7c745ca57a9a1ba1a5b9
https://doi.org/10.1158/1078-0432.c.6526929
https://doi.org/10.1158/1078-0432.c.6526929
Autor:
Seth A. Ettenberg, William R. Sellers, Carlos L. Arteaga, Alwin Schuller, Joshua Murtie, Kara Herlihy, Analeah B. Heidt, Christian Kunz, Winfried Elis, Manuela Haberl, Carolin Zehetmeier, Nicole Haubst, Alan Huang, Jian Gu, Rebecca Mosher, Rita Das, Jinsheng Liang, Huiqin Wang, Yan Chen, Dongshu Chen, Cammie R. Sutton, Parmita Saxena, Olga Sineshchekova, Sharon Li, Qing Sheng, Joan T. Garrett, Elizabeth R. Sprague, Carl U. Bialucha, Andrew P. Garner
PDF file - 268K, Figure S2. LJM716 inhibits HER3 mediated PI3K signaling.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45aed25076d0e9d1013eb0646b27aeb1
https://doi.org/10.1158/0008-5472.22396491.v1
https://doi.org/10.1158/0008-5472.22396491.v1
Autor:
Seth A. Ettenberg, William R. Sellers, Carlos L. Arteaga, Alwin Schuller, Joshua Murtie, Kara Herlihy, Analeah B. Heidt, Christian Kunz, Winfried Elis, Manuela Haberl, Carolin Zehetmeier, Nicole Haubst, Alan Huang, Jian Gu, Rebecca Mosher, Rita Das, Jinsheng Liang, Huiqin Wang, Yan Chen, Dongshu Chen, Cammie R. Sutton, Parmita Saxena, Olga Sineshchekova, Sharon Li, Qing Sheng, Joan T. Garrett, Elizabeth R. Sprague, Carl U. Bialucha, Andrew P. Garner
PDF file - 459K, Figure S1. HER2, HER3 and members of the PI3K signaling pathway are activated in HER2 amplified cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86548e62b2a877ed8988ea2fa0e960b5
https://doi.org/10.1158/0008-5472.22396494.v1
https://doi.org/10.1158/0008-5472.22396494.v1